Dan Aridor Holdings completed investment round in a company that engaged in the discovery and development of therapeutic polypeptides. The development is based on a core, next generation, proprietary combinatorial biology, high throughput screening platform technology.
the company has next generation, proprietary combinatorial biology, high throughput screening platform technology. Operating in the fast growing, newly emerging, functional genomic field, The company core technology is positioned to be one of the leading biotechnology tools for drug discovery. This technology will significantly accelerate the drug discovery R&D phase and reduce attrition rate of new drug candidates.
